Chimera Biotec

Chimera Biotec is a German biotechnology company specializing in bioanalysis and ultra-sensitive immunoassay services. With over 20 years of experience, the company offers GLP/GCP bioanalytical support for all phases of drug discovery and development, particularly focusing on high demands for bioanalytical quality. Their expertise lies in the development, validation, and support of immunoassays, going beyond traditional ELISA methods with platforms such as Imperacer (Immuno-PCR), Simoa® (Quanterix), MSD, and high sensitivity ELISA. Chimera Biotec's unique approach allows clients to leverage their in-house platforms and only outsource specific case studies where improved sensitivities are required. The company works closely with clients, offering technology evaluation studies to select the ideal platform for each study, tailored to their individual expectations. Whether it's non-regulated discovery phase or GCP clinical phase support, or IND-enabling TOX under full GLP-regime, Chimera Biotec ensures the method validation aligns with the expectations of bioanalytical support, catering to various dosage levels and clinical stages. This 20-year-old company presents an opportunity for investors seeking to tap into the growing demand for bioanalytical services in the biotechnology industry. With its strong focus on immunoassay excellence and support for drug development programs, Chimera Biotec demonstrates the potential for growth and innovation in the evolving biotech sector.